Research Coverage of Japanese Listed Companies, Shared Research Inc

Shared Research

Our report is an authoritative Owner’s Manual on the company.
- A vital piece in the investor’s toolbox, our report allows you to uncover the essence of the business
- We pinpoint strengths and weaknesses; discuss strategy
- Our aim is to make deep knowledge about the company readily available, saving investors time and enabling dialogue

We offer our research as a service for Japanese corporates.
- Our in-depth reports allow them to better inform investors by presenting an unbiased third-party view of business fundamentals
- Our reports do not offer investment opinions and are free for all investors

We start our coverage with a substantial core report.
- We continuously update this report to reflect earnings, news flow, and any material developments
- We thoroughly interview management on a quarterly basis

Research Coverage of Japanese Listed Companies

Shared Research Inc

Pioneering research coverage of Japanese listed companies. Now customizable and interactive for global institutional investors. Corporate access reimagined.

Equity Bottom-Up

<ul><li>FY09/25 revenue was JPY72mn, with a net loss of JPY916mn, primarily from technology access fees from Claris Biotherapeutics.</li><li>FY09/26 forecasts JPY72mn revenue, JPY1.2bn SG&A expenses, and JPY1.2bn net loss, reflecting increased clinical and development costs.</li><li>Current assets decreased by JPY700mn, liabilities increased by JPY121mn, and net assets decreased by JPY799mn in FY09/25.</li></ul>

FY09/25 revenue was JPY72mn, with a net loss of JPY916mn, primarily from technology access fees from Claris Biotherapeutics.FY09/26 forecasts JPY72mn revenue, JPY1.2bn SG&A expenses, and JPY1.2bn net loss, reflecting increased clinical and development costs.Current assets decreased by JPY700mn, liabilities increased by JPY121mn, and net assets decreased by JPY799mn in FY09/25.

Kringle Pharma Inc (4884 JP): Full-year FY09/25 flash update